TATEN

Clinical Trial Program

Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor treatment

Phase II

Status

Recruiting

Tumour subtype:

HR+

Scenario

Locally Advanced or Metastatic

SPONSOR

SOLTI

COLLABORATORS

PRINCIPAL INVESTIGATORS

Aleix Prat, MD, PhD (Hospital Clínic de Barcelona)
Eva Mª Ciruelos, MD, PhD (Hospital Universitario 12 de octubre, Madrid)

Sites

HOSPITAL CLINIC DE BARCELONA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL QUIRONSALUD SAGRADO CORAZON, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, ICO HOSPITALET (DURAN I REYNALS), INSTITUTO VALENCIANO DE ONCOLOGÍA